Yoshikatsu Eto

Yoshikatsu Eto, MD, PhD (2005 - 2008)Tokyo Jikei UniversityDept. Of Gene TherapyNishishinbashi 3-25-8, Minatoku-kuTokyo 105Japan

Yoshikatsu Eto, MD, PhD (2005 - 2008)Tokyo Jikei UniversityDept. Of Gene TherapyNishishinbashi 3-25-8, Minatoku-kuTokyo, 105-8461Japan

Yoshikatsu Eto

Tokyo Jikei University School of Medicine

Yoshikatsu Eto, MD, PhD (2005 - 2008)
...
Yoshikatsu Eto, MD, PhD (2005 - 2008)

Yoshikatsu Eto, MD, PhD (2001 - 2004)

Yoshikatsu Eto, M.D., Chairman and Professor in the Department of

"I am very pleased that enzyme replacement therapy with Aldurazyme has finally been approved in Japan for the treatment of MPS I," stated Yoshikatsu Eto, M.D., Chairman and Professor in the Department of Pediatrics at Tokyo Jikei University Hospital located in Tokyo, Japan.

"The approval of Fabrazyme has been eagerly anticipated by many Japanese physicians, Fabry patients and their families," said Yoshikatsu Eto, M.D., professor and chairman of the Department of Pediatrics at the Tokyo Jikei University School of Medicine and principal investigator for Genzyme's study of Fabrazyme in Japan.

'The approval of Fabrazyme has been eagerly anticipated by many Japanese physicians, Fabry patients and their families,' said Yoshikatsu Eto, M.D., professor and chairman of the Department of Pediatrics at the Tokyo Jikei University School of Medicine and principal investigator for Genzyme's study of Fabrazyme in Japan.